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Lysosomal disorders are a heterogeneous group of Over 40 inherited 
disorders that individually are rare but as a group have an incidence of 1 in 
10000 live births. LDs are caused by enzyme, enzyme activator, membrane 
transporter, or membrane protein defects that result in accumulation of 
complex macromolecules normally degraded in lysosomes .LDs classified 
to Mucopolysaccharidoses, disorders of lysosomal enzyme localization 
(Mucolipidoses), sphingolipidoses, sialic acid disorders, Oligosaccharidoses, 
Neuronal ceroid lipofuscinoses and  a number of disease that are more difficult 
to classify in to specific category such as Wolman disease and cystinosis 
 Ox/ostisis, pompe disease Danon disease.
Biochemical and genetic diagnosis of LSDs should be performed in specialized 
laboratories. Various clinical samples can be used for analysis, such as blood, 
urine, amniotic fluid, skin fibroblasts and tissue biopsies.
Measurement of the accumulated substrate is often the first approach when 
an LSD is suspected or in screening programmes. Specific secondary changes 
may also occur in cells associated with a lysosomal deficiency. Such changes 
may result in the modification of other proteins or cellular components 
that may be useful as markers of specific diseases, or for following disease 
progression. Identification of the molecular basis of a disorder may enable the 
use of more specific testing, such as the assessment of lysosomal enzymes and 
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The tests performed for diagnosis can be divided into the six categories 
outlined below:
Urinary oligosaccharides Urinary oligosaccharide screening is performed 
by high-performance thin-layer chromatography (HPTLC) .This method, 
however, has severe limitations. Metabolite quantification is not possible, and 
the identification of metabolites is assumed on the basis of migration rates. 
Definitive identification of specific metabolites is therefore not possible. This 
screening technique can provide an initial indication of a possible diagnosis, 
although further investigations are needed to confirm the diagnosis. abnormal 
HPTLC profile are:
Urinary glycosaminoglycans Mucopolysaccharidoses (MPS) may be 
suspected from measurements of urinary glycosaminoglycans (GAGs).This 
method assesses the amount of hexuronic acid contained in the extracted 
GAGs and can give false-negative results when the accumulated GAG is 
keratin sulphate, which contains galactose instead of hexuronic acid; in this 
case the diagnosis of Morquio disease may be missed.The second pitfall when 
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quantifying GAGs is linked to the progressive decrease 
of urinary GAG levels that occurs with age. In the 
case of MPS, the normal age-related decline in urinary 
GAGs should be taken into account when diagnosis 
is suspected in older individuals. One-dimensional 
electrophoresis is used to separate the main classes 
of GAGs: chondroitin sulphate, keratan sulphate, 
dermatan sulphate and heparan sulphate . In the normal 
physiological situation, only chondroitin sulphate is 
detectable, except in the urine of newborns, where 
a band corresponding to heparan sulphate may be 
present. Although urinary GAG levels may be affected 
by nutrient levels and drugs, the detection of keratan 
sulphate, dermatan sulphate and heparan sulphate may 
suggest the possibility of an MPS.
Global tests Recognition of the high combined 
prevalence of LSDs and the increasing availability 
of specific therapies have encouraged the search for 
reliable biomarkers that can be used to identify LSDs 
in newborns or in high-risk populations. It has been 
suggested that LAMP-1, LAMP-2, saposins and GM2-
ganglioside are elevated in almost all LSDs. 
Assessment of specific substrates The development 
of tandem mass spectrometry for the identification and 
quantification of lysosomal substrates and metabolites 
has been a significant advance in the diagnosis of 
LSDs .In almost all cases, glycosphingolipids and 
oligosaccharides analysed by this method have been 
shown to differ significantly in controls and affected 
patients: 12 diseases were identified in 47 patients, with 
only two cases not presenting with an elevation of the 
corresponding substrate 
Assessment of lysosomal enzyme activities
Lysosomal enzyme activities are usually determined by 
a fluorometric assay in cultured fibroblasts, leukocytes or 
sera, using a 4-methylumbelliferyl-containing fluorescent 
substrate. The activity of another lysosomal enzyme 
should also be assayed as a control for cell integrity.
LSDs can be associated with either low or undetectable 
enzyme activity. In some diseases, a correlation has 
been found between the level of residual enzyme 
activity and phenotypic severity 
It is noteworthy that, in some cases, lysosomal enzyme 
activity in vitro can be low in samples taken from 
individuals who do not have an LSD, a condition termed 
pseudodeficiency. Such pseudodeficiency has been 
reported for β-galactocerebrosidase, β-glucuronidase, 
β-glucosidase, β-hexosaminidase A and arylsulphatase 
A, and is linked to specific mutations 
Indirect biomarkers Indirect biomarkers may be 
useful for the identification of LSDs and for monitoring 
the effects of treatment. For example, increased plasma 
levels of two molecules, chitotriosidase and CC 18/
pulmonary and activation-regulated chemokine 
(PARC), have been reported in patients with Gaucher 
disease.
Molecular genetics
LSDs are monogenic diseases, the majority of which 
have an autosomal recessive mode of inheritance. 
To date, X-linked inheritance has been observed in 
Hunter disease, Fabry disease and Danon disease. 
Identification of the mutations responsible for the LSDs 
has facilitated understanding of the pathophysiology of 
these diseases. It also enables prenatal and postnatal 
testing and allows the provision of genetic counselling.
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